Adalimumab and infliximab are equally efficient in achieving sustained remission in ulcerative colitis but infliximab is superior in severe disease—a retrospective observational study

Key Points

• This research aims to compare the effectiveness of adalimumab and infliximab for achieving sustained remission in ulcerative colitis patients.
• Retrospective analysis of bio-naive patients with ulcerative colitis
• Comparison of remission rates between adalimumab and infliximab
• Evaluation of remission induction specifically in severe disease cases
• Both adalimumab and infliximab achieved similar long-term remission rates
• Infliximab showed superior effectiveness in inducing remission in severe cases